Cyclazocine: Comparison to hydromorphone and interaction with cocaine

Behavioural Pharmacology

Volumn 15, Issue 2, 2004, Pages 91-102

  Preston, K L ^a   Umbricht, A ^a,b   Schroeder, J R ^a   Abreu, M E ^a,c   Epstein, D H ^a   Pickworth, W B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Shire Pharmaceutical Devmt Inc   (United States)

Author keywords

Cocaine; Cyclazocine; Humans; Hydromorphone; Kappa opiolds; Opioids

Indexed keywords

COCAINE; CYCLAZOCINE; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST;

ADULT; ARTICLE; ATTENUATION; BEHAVIOR; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; MALE; OPIATE ADDICTION; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; COCAINE; COCAINE-RELATED DISORDERS; CYCLAZOCINE; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROMORPHONE; MALE; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 1942453125     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200403000-00001     Document Type: Article

References (76)

1. Acri JB, Thompson AC, Shippenberg T (2001). Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 39:343-50.
2. Archer S, Glick SD, Bidlack JM (1996). Cyclazocine revisited. Neurochem Res 21:1389-1373.
3. Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK (2003). Effects of mixed-action mu/kappa opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28:1125-1139.
4. Collins SL, D'Addario C, Izenwasser S (2001). Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission. Eur J Pharmacol 426:25-34.
5. Corrigall WA, Coen KM, Adamson KL, Chow BLC (1999). The mu opioid agonist DAMGO alters the intravenous self-administration of cocaine in rats: mechanisms in the ventral tegmental area. Psychopharmacology (Berl) 141:428-435.
6. Di Chiara G, Imperato A (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080.
7. 6 glioma cell line expressing the μ opioid receptor. J Pharmacol Exp Ther 278:1121-1127.
8. Foltin RW, Fischman MW (1992). The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J Pharmacol Exp Ther 261:623-632.
9. Foltin RW, Fischman MW (1996). Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther 278:1153-1164.
10. Foltin RW, Christiansen I, Levin FR, Fischman MW (1995). Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. J Pharmacol Exp Ther 275:38-47.
11. Frank A, Moll A, Hort J (1982). A comparison of three ways of measuring pain. Rheumatol Rehabil 21:211-217.
12. Freedman AM, Fink M, Sharoff R, Zaks A (1967). Cyclazocine and methadone in narcotic addiction. JAMA 202:191-194.
13. Gharagozlou P, Demirci H, Clark JD, Lameh J (2003). Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 3:1.
14. Glick SD, Wisker KE, Maisonneuve IM (1998). Effects of cyclazocine on cocaine self-administration in rats. Eur J Pharmacol 357:9-14.
15. Haertzen CA (1970). Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI). Psychopharmacology (Berl) 18:366-377.
16. Heidbreder CA, Babovic-Vuksanovic D, Shoaib M, Shippenberg TS (1995). Development of behavioral sensitization to cocaine: Influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 275:38-47.
17. Hurd YL, Herkenham M (1993). Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13:357-369.
18. 2 receptors. Synapse 30:275-283.
19. Jasinski DR, Martin WR, Sapira JD (1968). Antagonism of the subjective, behavioral, pupillary and respiratory depressant effects of cyclazocine by naloxone. Clin Pharmacol Ther 8:215-222.
20. Kantak KM, Riberdy A, Spealman RD (1999). Cocaine-opioid interactions in groups of rats trained to discriminate different dosea of cocaine. Psychopharmacology (Berl) 147:257-265.
21. Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D (1986). Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968.
22. Lasagna L, DeKornfeld TJ, Pearson JW (1964). The analgesic efficacy and respiratory effects in man of a benzomorphan narcotic antagonist. J Pharmacol Exp Ther 144:12-16.
23. Leander D (1983). A kappa opioid effect: Increased urination in the rat. J Pharmacol Exp Ther 224:89-94.
24. Lezak MD (1995.) Neuropsychological Assessment. 3rd ed. New York: Oxford University Press; pp. 683-684.
25. Maisonneuve IM, Archer S, Glick SD (1994). U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60.
26. Martin WR (1983). Pharmacology of opioids. Pharmacol Rev 35:283-323.
27. Martin WR, Fraser HF, Gorodetzky CW, Rosenberg DE (1965). Studies on the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl- 2′-hydroxy-5-9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20, 740, ARC II-C-3). J Pharmacol Exp Ther 150:426-436.
28. Martin WR, Gorodetzky CW, McClane TK (1966). An experimental study in the treatment of narcotic addicts with cyclazocine. Clin Pharmacol Ther 7:455-465.
29. Martin WR, Sloan JW, Sapiro JD, Jasinski DR (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12: 31-37.
30. Mash DC, Staley JK (1999). D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann NY Acad Sci 877:507-522.
31. McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982). An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14:463-466.
32. Mello NK, Negus SS (1998). Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812-824.
33. Miller DK, Nation JR, Bratton GR (2001). The effects of perinatal exposure to lead on the discriminative stimulus properties of cocaine and related drugs in rats. Psychopharmacology (Berl) 158:165-174.
34. Nann-Vernotica E, Donny EC, Bigelow GE, Walsh SL (2001). Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology (Berl) 155:338-347.
35. Negus SS, Mello NK (1999). Effects of kappa opioid agonists on the discriminative stimulus effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol 7:307-317.
36. Negus SS, Mello NK, Portoghese PS, Lin C-E (1997). Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282:44-55.
37. Pickworth WB, Neidert GL, Kay DC (1986). Cyclazocine-induced sleep disruptions in nondependent addicts. Prog Neuropsychopharmacol Biol Psychiatry 10:77-85.
38. Preston KL, Bigelow GE (1993). Differential naltrexone antagonism of hydromorphone and pentazocine in human volunteers. J Pharmacol Exp Ther 264:813-823.
39. Preston KL, Bigelow GE, Liebson IA (1988). Butorphanol-precipitated withdrawal in methadone-dependent humans. J Pharmacol Exp Ther 246:441-448.
40. Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989). Drug discrimination in human post-addicts: Agonist-antagonist opioids. J Pharmacol Exp Ther 250:184-196.
41. Preston KL, Sullivan JT, Strain EC, Bigelow GE (1996). Enhancement of cocaine's abuse liability in methadone maintenance patients. Psychopharmacology (Berl) 123:15-25.
42. Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagoplan R (1994). Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 34:1126-1132.
43. 6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther 288:827-833.
44. Rosin A, Lindholm S, Franck J, Georgieva J (1999). Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens. Neurosci Lett 275:1-4.
45. Rosin A, van der Ploeg I, Georgieva J (2000). Basal and cocaine-induced opioid receptor gene expression in the rat CNS analyzed by competitive reverse transcription PCR. Brain Res 872:102-109.
46. Schenk S, Partridge B (2001). Effect of the kappa-opioid receptor agonist, U6959, on reinstatement of extinguished amphetamine self-administration behavior. Pharmacol Biochem Behav 68:629-634.
47. Schenk S, Partridge B, Shippenberg TS (1999). U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug seeking. Psychopharmacology (Berl) 144:339-346.
48. Schenk S, Partridge B, Shippenberg TS (2000). Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl) 151:85-90.
49. Schenk S, Partridge B, Shippenberg TS (2001). Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology 24:441-450.
50. Shippenberg TS, LeFevour A, Thompson AC (1998). Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the κ-opioid receptor agonist U69593. Eur J Pharmacol 345:27-34.
51. Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA (2001). Modulation of the behavioral and neurochemical effects of psychostimulants by κ-opioid receptor systems. Ann NY Acad Sci 937:50-73.
52. Smith MA, Gordon KA, Craig CK, Bryant PA, Ferguson ME, French AM, et al. (2003). Interactions between opioids and cocaine on locomotor activity in rats: influence of the opioid's relative efficacy at the mu receptor. Psychopharmacology (Berl) 167:265-273.
53. Spangler R, Zhou Y, Maggos CE, Zlobin A, Ho A, Kreek MJ (1996). Dopamine antagonist and 'binge' cocaine effects on rat opioid and dopamine transporter mRNAs. Neuroreport 7:2196-2200.
54. Spangler R, Zhou Y, Maggos CE, Schlussman SD, Ho A, Kreek MJ (1997). Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute 'binge' cocaine. Brain Res Mol Brain Res 44:139-142.
55. Spealman RD, Bergman J (1992). Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J Pharmacol Exp Ther 261: 607-615.
56. Spealman RD, Bergman J (1994). Opioid modulation of the discriminative stimulus effects of cocaine: comparison of mu, kappa and delta agonists in squirrel monkeys discriminating low doses of cocaine. Behav Pharmacol 5:21-31.
57. Staley JK, Rothman RB, Rice KC, Partella J, Mash DC (1997). K2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci 17:8225-8233.
58. Strain EC, Preston KL, Stitzer ML, Liebson IA, Bigelow GE (1994). The effects of cocaine in buprenorphine-maintained outpatient volunteers: Results from clinical experience and laboratory challenges. Am J Addict 3:129-143.
59. Suzuki T, Mori T, Tsuji M, Maeda J, Kishimoto Y, Misawa M, et al. (1997). Differential effects of mu-, delta- and kappa-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats. Eur J Pharmacol 324:21-29.
60. Thompson AC, Zapata A, Justice JB, Vaughan RA, Sharpe LG, Shippenberg TS (2000). Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20:9333-9340.
61. Turchan J, Przewlocka B, Lason W, Przewlocki R (1998). Effects of repeated psychostimulant administration on the prodynorphine system activity and kappa opioid receptor density in the rat brain. Neuroscience 85:1051-1059.
62. Ukai M, Mori E, Kameyama T (1997). Modulatory effects of morphine, U-50488 H and 1,3-di-(2-tolyl)guanidine on cocaine-like discriminative stimulus in the rat using two-choice discrete-trial avoidance paradigm. Methods Find Exp Clin Pharmacol 19:541-546.
63. Unterwald EM, Rubenfeld JM, Kreek M (1994). Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. J Neuroreport 5:1613-1616.
64. Unterwald EM, Kreek M, Cuntapay M (2001). The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res 900:103-109.
65. Vanderschuren LJMJ, Schoffelmeer ANM, Wardeh G, Devries TJ (2000). Dissociable effects of the kappa-opioid receptor agonists bremazocine U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine. Psychopharmacology (Berl) 150:35-44.
66. Vaupel DB, Lange WR, London ED (1993). Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans. J Pharmacol Exp Ther 267:1386-1394.
67. Waddell AB, Holtzman SG (1999). Modulation of cocaine-induced antinociception by opioid-receptor agonists. Pharmacol Biochem Behav 62:247-253.
68. Walker JM, Thompson LA, Frascella J, Friederich MW (1987). Opposite effects of mu and kappa opiates on the firing-rate of dopamine cells in the substantia nigra of the rat. Eur J Pharmacol 134:53-59.
69. Walsh SL, Preston KL, Sullivan JT, Fromme R, Bigelow GE (1994). Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14:396-407.
70. Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE (1996). Effects of naltrexone on response to intravenous cocaine, hydromorphone, and their combination in humans. J Pharmacol Exp Ther 279:524-538.
71. Walsh SL, Haberny KA, Bigelow GE (2000). Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology (Berl) 150:361-373.
72. Walsh SL, Geter-Douglas B, Strain EC, Bigelow GE (2001a). Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration. J Pharmacol Exp Ther 299: 147-158.
73. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001b). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157:151-162.
74. Woolfolk DR, Holtzman SG (1996). The effects of opioid receptor antagonism on the discriminative stimulus effects of cocaine and D-amphetamine in the rat. Behav Pharmacol 7:779-787.
75. Woolfolk DR, Holtzman SG (1997). Mu-, delta- and kappa-opioid receptor agonists do not alter the discriminative stimulus effects of cocaine or D-amphetamine in rats. Drug Alcohol Depend 48:209-220
76. Zubieta JK, Gorelick DA, Ravert HT, Dannals RF, Frost JJ (1996). Increased mu opioid receptor binding detected by PET in cocaine dependent men is associated with cocaine craving. Nature Med 2:1225-1229.